| Property | Value |
|---|---|
| Gene Symbol | TREM2 |
| Protein | TREM2 protein |
| Chromosomal Location | 6p21.1 |
| Primary Expression | Microglia |
| Key Adaptor | DAP12 (TYROBP) |
| AD Risk Variants | R47H, R62H, R64H, Q33X, Y38C |
| Associated Diseases | Alzheimer's disease, Nasu-Hakola disease, FTD |
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a critical microglial receptor that bridges innate immunity with neurodegeneration in Alzheimer's disease. As a master regulator of microglial function, TREM2 enables brain immune surveillance, phagocytosis of pathological aggregates, and metabolic adaptation to the diseased brain environment[1].
Rare coding variants in TREM2 confer 2-4x increased risk for Alzheimer's disease, comparable to carrying one APOE ε4 allele[2]. This genetic evidence, combined with compelling preclinical data, has made TREM2 one of the most intensively pursued therapeutic targets in neurodegenerative disease.
| Domain | Position | Function |
|---|---|---|
| Signal peptide | 1-18 | Secretory pathway targeting |
| Ig-like V-type | 19-122 | Ligand binding (lipids, ApoE, Aβ) |
| Stem region | 123-157 | Receptor stability |
| Transmembrane | 158-180 | DAP12 association |
| Cytoplasmic tail | 181-234 | No intrinsic signaling |
TREM2 functions as a lipid-sensing receptor that recognizes:
The TREM2-DAP12 complex activates multiple downstream pathways:
| Variant | Odds Ratio | Effect on Function | Discovery |
|---|---|---|---|
| R47H | ~3.0x | Strongly reduced lipid/ApoE binding | 2013 |
| R62H | ~2.0x | Reduced ligand binding | 2013 |
| R64H | ~2.0x | Partial loss of function | 2013 |
| Q33X | ~5.0x | Truncated protein (null) | 2015 |
| Y38C | ~3.0x | Impaired receptor trafficking | 2014 |
| D87N | ~1.5x | Moderate functional impact | 2013 |
| H157Y | Variable | Altered receptor processing | 2019 |
The AD-associated TREM2 variants all impair microglial function through distinct mechanisms:
Biallelic loss-of-function mutations in TREM2 cause Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy), characterized by:
This demonstrates that complete TREM2 deficiency is sufficient to cause neurodegeneration in humans.
TREM2 is required for the transition from homeostatic microglia to the DAM phenotype:
| State | TREM2 Status | Characteristics |
|---|---|---|
| Homeostatic | Normal | P2RY12+, TMEM119+, process extension |
| DAM Stage 1 | TREM2-independent | APOE upregulation, some inflammatory genes |
| DAM Stage 2 | TREM2-dependent | Phagocytic genes, lysosomal genes, lipid metabolism |
| Dysfunctional | Impaired | Failed DAM transition, reduced phagocytosis |
When TREM2 signaling is impaired:
TREM2 agonists aim to enhance microglial function:
Rationale:
Clinical Candidates:
| Drug | Company | Mechanism | Phase | Status |
|---|---|---|---|---|
| AL002 | Alector/GSK | Anti-TREM2 mAb agonist | Phase 2 | Recruiting (2024) |
| AL003 | Alector | TREM2 agonist | Phase 1 | Completed |
| SBT92900 | Shinebotamab/Alector | TREM2 agonist | Phase 1 | Completed |
| BIA 28-4406 | BioAegis Therapeutics | rhTREM2-Fc fusion | Preclinical | IND-enabling |
TREM2 antagonists have been explored but are less advanced:
Rationale:
Note: Most current development focuses on agonists rather than antagonists, as the net effect of TREM2 activation appears beneficial in AD.
| Trial ID | Drug | Phase | Population | Primary Endpoint | Status |
|---|---|---|---|---|---|
| NCT05122897 | AL002 | Phase 2 | Early AD | Safety, CSF biomarkers | Recruiting |
| NCT04592874 | AL002 | Phase 1 | Healthy volunteers | Safety, PK | Completed |
| NCT03822208 | AL003 | Phase 1 | AD | Safety, target engagement | Completed |
Clinical trials monitor target engagement through:
| Target | Expression | Function | AD Risk | Therapeutic Status |
|---|---|---|---|---|
| TREM2 | Microglia, myeloid | Phagocytosis, DAM | Strong | Phase 2 |
| TYROBP/DAP12 | Microglia | TREM2 adaptor | Moderate | Preclinical |
| CD33 | Microglia | Inhibitory receptor | Strong | Phase 1 |
| CSF1R | Microglia | Proliferation, survival | Weak | Phase 1/2 |
| CX3CR1 | Microglia, neurons | Neuroimmune communication | Weak | Preclinical |
| P2RY12 | Homeostatic microglia | Chemotaxis | None known | Research |
| Feature | TREM2 | CD33 |
|---|---|---|
| Effect | Activating | Inhibitory |
| Ligands | Lipids, ApoE, Aβ | Sialic acids |
| AD risk variants | Multiple (R47H, etc.) | rs3865444 |
| Therapeutic | Agonist approach | Antagonist approach |
| Feature | TREM2 | CSF1R |
|---|---|---|
| Primary effect | Functional activation | Proliferation |
| Target cell | Mature microglia | Progenitors + mature |
| Risk association | Strong genetic | Less clear |
| Development stage | Phase 2 | Phase 1 |
TREM2 remains the top microglial target because:
TREM2 plays a critical role in regulating microglial polarization states, which is fundamental to understanding its neuroprotective functions. Microglia can adopt pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes in response to environmental cues, and TREM2 signaling strongly influences this balance.
TREM2 activation promotes the adoption of an anti-inflammatory, neuroprotective M2-like phenotype characterized by increased expression of arginase-1 (Arg1), Ym1, and CD206. This polarization shift is mediated through downstream activation of PI3K/AKT and SYK signaling pathways, which suppress pro-inflammatory gene programs while upregulating genes associated with tissue repair and phagocytosis[7].
Studies have demonstrated that TREM2 engagement enhances microglial metabolic fitness, promoting oxidative phosphorylation and mitochondrial function over glycolysis—a metabolic signature associated with the M2 phenotype.
TREM2 signaling exerts significant modulatory effects on cytokine release from microglia. Under baseline conditions, TREM2 suppresses the production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6 through inhibition of NF-κB signaling pathways.
During active phagocytosis, TREM2 promotes release of anti-inflammatory cytokines such as IL-10 and TGF-β while suppressing excessive inflammatory responses. This balanced cytokine profile supports tissue homeostasis.
TREM2 also inhibits NLRP3 inflammasome assembly and activation, reducing mature IL-1β release and preventing pyroptotic cell death[8].
Loss-of-function mutations or deficiency in TREM2 results in a hyper-inflammatory microglial state:
TREM2 haploinsufficiency (as seen in the R47H AD risk variant) is sufficient to impair microglial function and increase disease susceptibility[9].
Several pharmaceutical companies are developing TREM2-targeting agonist antibodies:
AL002 (Alector/Inverness): A monoclonal antibody that binds TREM2 and enhances downstream signaling. Currently in Phase 2 clinical trials for early Alzheimer's disease. The antibody promotes microglial survival and phagocytosis while reducing inflammatory responses.
DNL788 (Denali Therapeutics): Another TREM2 agonist antibody program targeting the same pathway through a distinct epitope.
Gene therapy represents a promising avenue for sustained TREM2 modulation:
Small molecule TREM2 modulators are being actively investigated:
["Deczkowska et al. TREM2 physiology and pathology (2020)". 2020. ↩︎
["Guerreiro et al. TREM2 variants in Alzheimer's disease (2013)". 2013. ↩︎
["Wang et al. TREM2 lipid sensing sustains microglial response (2015)". 2015. ↩︎
["Zhou et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent cellular responses (2020)". 2020. ↩︎
["Schlepckow et al. Enhancing protective microglial activities with a TREM2 agonist (2020)". 2020. ↩︎
["Hansen et al. TREM2 in Alzheimer's disease clinical development (2024)". 2024. ↩︎
Wang Y, Cella M, Mallinson K, et al. TREM2 sustains microglial expansion during aging and response to demyelination. 2015. ↩︎
Ulland TK, Song WM, Huang SC, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. 2017. ↩︎
Leyns CEG, Ulrich JD, Finn MB, et al. TREM2 deficiency impairs microglial Aβ clearance. 2017. ↩︎